1. Home
  2. AMTB vs CRVS Comparison

AMTB vs CRVS Comparison

Compare AMTB & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Amerant Bancorp Inc.

AMTB

Amerant Bancorp Inc.

HOLD

Current Price

$24.67

Market Cap

894.1M

Sector

Finance

ML Signal

HOLD

Logo Corvus Pharmaceuticals Inc.

CRVS

Corvus Pharmaceuticals Inc.

HOLD

Current Price

$12.94

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMTB
CRVS
Founded
1979
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
894.1M
1.0B
IPO Year
2018
2016

Fundamental Metrics

Financial Performance
Metric
AMTB
CRVS
Price
$24.67
$12.94
Analyst Decision
Buy
Strong Buy
Analyst Count
3
6
Target Price
$23.67
$30.17
AVG Volume (30 Days)
223.2K
1.2M
Earning Date
04-23-2026
05-07-2026
Dividend Yield
1.57%
N/A
EPS Growth
386.36
48.04
EPS
0.44
N/A
Revenue
N/A
N/A
Revenue This Year
$8.29
N/A
Revenue Next Year
$7.67
N/A
P/E Ratio
$55.14
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.62
$3.71
52 Week High
$24.38
$26.95

Technical Indicators

Market Signals
Indicator
AMTB
CRVS
Relative Strength Index (RSI) 66.64 55.21
Support Level $21.68 $11.13
Resistance Level N/A $14.00
Average True Range (ATR) 0.62 0.68
MACD 0.15 0.27
Stochastic Oscillator 97.21 90.95

Price Performance

Historical Comparison
AMTB
CRVS

About AMTB Amerant Bancorp Inc.

Amerant Bancorp Inc is a bank holding company. Through its bank, it provides individuals and businesses deposit, credit, investment, wealth management, and fiduciary services, both in the United States and to select international customers. The bank also provides banking services through traditional channels, such as banking centers and ATMs, as well as via secure websites, mobile devices and telephones.

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.

Share on Social Networks: